BofA analysts added Argenx (ARGX) to the firm’s “US 1 List,” which represents a collection of the best ideas from its equity research analysts.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Efgartigimod PH20 SC Study: A Potential Game-Changer for Inflammatory Myopathy
- Argenx’s New CIDP Study: Transitioning to Efgartigimod PH20 SC
- Argenx’s Pediatric Study on Efgartigimod PH20 SC: A Potential Game-Changer for Generalized Myasthenia Gravis
- Argenx’s Efgartigimod Study: A Potential Breakthrough for Pediatric Myasthenia Gravis
- Argenx’s Promising Phase 3 Study on Efgartigimod IV for ITP: A Market Game-Changer?